Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference
Kyntra Bio (Nasdaq: KYNB) will present at the 25th Annual Needham Virtual Healthcare Conference April 13-16, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kyntra Bio (Nasdaq: KYNB) will present at the 25th Annual Needham Virtual Healthcare Conference April 13-16, 2026. CEO Thane Wettig will deliver the company presentation on April 13, 2026 at 1:30 PM EDT. A live webcast and a 90-day replay will be available on the company website.
Management will be available for one-on-one meetings via Needham representative requests.
Details
News Market Reaction – KYNB
On Apr 9, the first trading day after this news, KYNB closed 1.51% below the previous close.
Data tracked by StockTitan Argus for the Apr 9 session.
Key Figures
- Conference dates
- April 13–16, 2026
- 25th Annual Needham Virtual Healthcare Conference
- Presentation time
- 1:30 PM EDT
- Company presentation on Monday, April 13, 2026
- Replay availability
- 90 days
- Replay on Kyntra Bio Events & Presentations page
- Conference edition
- 25th Annual
- Needham Virtual Healthcare Conference
Historical Context
-
Q4/FY2025 financials plus clinical and cash runway updates.
-
Announcement of timing for Q4/FY2025 results and conference call.
-
Positive Phase 1b/2 data for FG-3246 combo in mCRPC.
-
Planned participation in Oppenheimer and Leerink healthcare conferences.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, April 08, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced that the Company will present at the 25th Annual Needham Virtual Healthcare Conference being held April 13-16, 2026.
Thane Wettig, Chief Executive Officer of Kyntra Bio, will deliver a company presentation on Monday, April 13, 2026, at 1:30 PM EDT. A live webcast of the presentation will be available here.
Kyntra Bio’s management team will be available for one-on-one meetings during the conference. Interested investors should contact their representative at Needham. A replay of the presentation will be posted, when available, to the Kyntra Bio website on the Events & Presentations page of the Investors and Media section for 90 days.
About Kyntra Bio
Kyntra Bio is a biopharmaceutical company focused on development of novel therapies in oncology and rare disease. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in Europe, Japan, China, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate the development plan for the Phase 3 trial of roxadustat in anemia associated with lower-risk myelodysplastic syndromes (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase 2 development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit www.kyntrabio.com.
For Investor Inquiries:
David DeLucia, CFA
Senior Vice President and Chief Financial Officer
ir@kyntrabio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.